Mistral Pharma Inc.
TSX VENTURE : MIP

Mistral Pharma Inc.

August 31, 2007 07:50 ET

Mistral Pharma Announces Licensing of a Patent Application for MIST-B02

MONTREAL, QUEBEC--(Marketwire - Aug. 31, 2007) - Mistral Pharma Inc. (TSX VENTURE:MIP) ("Mistral") announced today that it has licensed a method of use patent application from La Societe Therapprouve Inc., related to a new gastroenterology therapeutic indication for the drug included in Mistral's MIST-B02. As part of this licensing agreement, La Societe Therapprouve Inc. was granted 150,000 options to acquire common share of Mistral at a price of $0.10 per share, subject to vesting provisions. This grant was made pursuant to the stock options plan of Mistral.

"This licensing deal further increases the value of our MIST-B02 product to potential pharmaceutical partners" said Bertrand Bolduc, Mistral's President & CEO. "With a formulation and a patent application, MIST-B02 represents a very interesting product, especially for the US market where it would be a new chemical entity" he added. Mistral's second product, MIST-B02, is a controlled-delivery branded product in the gastroenterology field. MIST-B02 is targeting a brand product with more than US$ 100 M in worldwide annual sales.

About Mistral Pharma Inc.

Mistral Pharma is an innovative pharmaceutical product development and drug delivery company. Its first two branded drug delivery products, MIST-B01 & B02, showed positive results at their respective first pilot clinical trials. Mistral also has the Canadian rights to Instillagel®, a local anesthetic and antiseptic combination product used for urology procedures which is expected to be launched in Canada during Q4 2007. Mistral positions itself as a development and marketing partner for pharmaceutical companies. Additional information about Mistral Pharma can be obtained on Mistral Pharma's website at www.mistralpharma.com.

Forward-looking Statements

Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of Mistral Pharma. These statements are based on suppositions and uncertainties as well as on management's best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for Mistral Pharma's products, the impact of price pressures exerted by competitors, and general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

Contact Information

  • Mistral Pharma Inc.
    Bertrand F. Bolduc, B.Pharm., MBA
    President & Chief Executive Officer
    514-421-1717 # 2224
    bbolduc@mistralpharma.com
    or
    Mistral Pharma Inc.
    Alain Provencher, CA, CF
    Vice-president, Finance & Chief Financial Officer
    514-421-1717 # 2222
    aprovencher@mistralpharma.com